ACURA PHARMACEUTICALS INCORPORATED (OTCMKTS:ACUR) Has Decline in Shorts

June 20, 2017 - By Vivian Park

The stock of ACURA PHARMACEUTICALS INCORPORATED (OTCMKTS:ACUR) registered a decrease of 4.66% in short interest. ACUR’s total short interest was 36,800 shares in June as published by FINRA. Its down 4.66% from 38,600 shares, reported previously. With 35,300 shares average volume, it will take short sellers 1 days to cover their ACUR’s short positions.

It closed at $0.51 lastly. It is down 0.00% since June 20, 2016 and is . It has underperformed by 16.70% the S&P500.

Acura Pharmaceuticals, Inc. is a pharmaceutical company. The company has market cap of $6.06 million. The Firm is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. It currently has negative earnings. The Firm has discovered and developed three platform technologies, which can be used to develop multiple products.

More notable recent Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) news were published by: Quotes.Wsj.com which released: “News Acura Pharmaceuticals Inc.ACUR” on February 13, 2011, also Marketwired.com with their article: “Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial …” published on February 29, 2016, Globenewswire.com published: “Delisting of Securities of Spanish Broadcasting System, Inc., Acura …” on March 13, 2017. More interesting news about Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) were released by: Marketwatch.com and their article: “Acura Pharmaceuticals approves one-for-five reverse stock split” published on August 24, 2015 as well as Seekingalpha.com‘s news article titled: “Acura Pharmaceuticals Is Grossly Undervalued And Poised For Rapid Growth” with publication date: May 17, 2013.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.